helping Novo Nordisk to a record operating profit up 37% to DKK 75.8 billion. The performance is remarkable as both Ozempic and Wegovy are subject to rationing at the moment as demand outstrips ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... P 500 and the Dow Jones Industrial Average reached new record highs, marking six consecutive weeks of gains for ...

Novo Nordisk (NVO) reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy. Novo announced an earnings per ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly ... using data from electronic health records in the US. The paper, published Thursday in the journal Alzheimer’s & Dementia ...

Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes, an analysis of medical records found, supporting the case for ...

Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records. The findings suggest that Ozempic ...